A comprehensive view of Merck & Co. Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Merck to acquire the University at Buffalo startup Abceutics for up to US$280.0M in a bid to enhance its antibody-drug conjugate pipeline; Abceutics is developing technology aimed at reducing the impact of therapies on healthy cells
Published: April 08, 2024 by FierceBiotech
Merck initiates Phase 3 clinical trial of MK-1084, an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA (pembrolizumab) for first-line treatment of certain patients with metastatic non-small cell lung cancer
Published: April 04, 2024 by Merck & Co. Inc.
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients With Platinum-Resistant Ovarian Cancer
Published: April 03, 2024 by Merck & Co. Inc.
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Published: April 01, 2024 by Merck & Co. Inc.
Merck to hold first-quarter 2024 sales and earnings conference call April 25
Published: April 01, 2024 by Business Wire

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count